Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MoonLake Immunotherapeutics (MLTX : NSDQ)

• Company Description    MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $10.63 Daily Weekly Monthly 20 Day Moving Average: 3,131,656 shares Shares Outstanding: 64.23 (millions) Market Capitalization: $682.77 (millions) Beta: 1.13 52 Week High: $62.75 52 Week Low: $5.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.61% 0.89% 12 Week -80.46% -81.27% Year To Date -80.37% -82.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL DORFSTRASSE 29 - ZUG,V8 6300 CHE ph: 41-41-510-8022 fax: - ir@moonlaketx.com http://www.moonlaketx.com

• General Corporate Information    Officers Jorge Santos da Silva - Chief Executive Officer; Director Simon Sturge - Chairperson; Director Matthias Bodenstedt - Chief Financial Officer Spike Loy - Director Catherine Moukheibir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61559X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 64.23 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $682.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -96.43% vs. Previous Quarter: -26.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -55.57 06/30/25 - -40.98 03/31/25 - -30.81 ROA 09/30/25 - -45.18 06/30/25 - -35.81 03/31/25 - -28.40 Current Ratio 09/30/25 - 8.50 06/30/25 - 16.65 03/31/25 - 21.11 Quick Ratio 09/30/25 - 8.50 06/30/25 - 16.65 03/31/25 - 21.11 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 4.53 06/30/25 - 5.58 03/31/25 - 6.45 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.25 06/30/25 - 0.21 03/31/25 - 0.18 Debt-to-Capital 09/30/25 - 20.21 06/30/25 - 17.01 03/31/25 - 15.04

Powered by Zacks Investment Research ©